Cardiol Therapeutics Company Executives

Cardiol Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (1.4883) % which means that it has lost $1.4883 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (3.4798) %, meaning that it generated substantial loss on money invested by shareholders. Cardiol Therapeutics' management efficiency ratios could be used to measure how well Cardiol Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of February 2026, Return On Tangible Assets is likely to drop to -1.39. In addition to that, Return On Capital Employed is likely to drop to -1.96. At this time, Cardiol Therapeutics' Total Assets are very stable compared to the past year. As of the 19th of February 2026, Other Current Assets is likely to grow to about 1.3 M, while Net Tangible Assets are likely to drop about 32.7 M. As of the 19th of February 2026, Common Stock Shares Outstanding is likely to drop to about 46.1 M. In addition to that, Net Loss is likely to drop to about (34.7 M)Cardiol Therapeutics holds a total of 111.68 Million outstanding shares. Cardiol Therapeutics Class shows 3.13 percent of its outstanding shares held by insiders and 20.5 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in stocks such as Cardiol Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Cardiol Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Cardiol Therapeutics Workforce Comparison

Cardiol Therapeutics Benchmark Summation

Cardiol Therapeutics Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Cardiol Therapeutics often depends on how effective the management is. Cardiol Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cardiol management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cardiol management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.